Evidence map›Paper›PMID 29848707›Full record

ArticleAnticancer research2018

Second Primary Malignancies in Patients with Well-differentiated/Dedifferentiated Liposarcoma.

Eric Jung, Marco Fiore, Alessandro Gronchi, Valerie Grignol, Raphael E Pollock, Susan S Chong, Shefali Chopra, Ann S Hamilton, William W Tseng

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Anticancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Eric JungDepartment of Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA, U.S.A.
Marco FioreDepartment of Surgery, IRCCS Foundation National Tumor Institute, Milan, Italy.
Alessandro GronchiDepartment of Surgery, IRCCS Foundation National Tumor Institute, Milan, Italy.
Valerie GrignolDepartment of Surgery, The James Comprehensive Cancer Center, Ohio State University, Columbus, OH, U.S.A.
Raphael E PollockDepartment of Surgery, The James Comprehensive Cancer Center, Ohio State University, Columbus, OH, U.S.A.
Susan S ChongDepartment of Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA, U.S.A.
Shefali ChopraDiscovery Research Program, Department of Pathology and Laboratory Medicine, University of Southern California, Los Angeles, CA, U.S.A.
Ann S HamiltonDepartment of Preventive Medicine, University of Southern California, Keck School of Medicine, Los Angeles, CA, U.S.A.
William W TsengDepartment of Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA, U.S.A. william.tseng@med.usc.edu.
University of Southern California · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

backgroundWell-differentiated/dedifferentiated (WD/DD) liposarcoma is a rare malignancy of putative adipocyte origin. To our knowledge, there have only been isolated case reports describing second primary cancer in patients with this disease. We report on a combined case series of such patients and explore the frequency of this occurrence using a national cancer database. MATERIALS AND

methodsDemographics and clinicopathological data were collected from patients with WD/DD liposarcoma who were found to have a concurrent or subsequent second primary cancer, at one of three sarcoma referral centers from 2014-2016. The Surveillance, Epidemiology and End Results (SEER) database was also queried to identify adult patients diagnosed with WD/DD liposarcoma between 1973-2012. Observed/expected (O/E) ratios of second primary malignancies among these cases were calculated by comparison to the age-adjusted cancer incidence in the general population using SEER*stat software.

resultsIn total, 26 out of 312 consecutive patients (8.3%) with WD/DD liposarcoma at our centers had a second primary cancer identified within 2 years of liposarcoma diagnosis. In the SEER database, among 1,845 patients with WD/DD liposarcoma, 75 (4.1%) had a second cancer within 2 years after liposarcoma diagnosis (O/E ratio=1.81, 99% confidence interval(CI)=1.33-2.40). Patients less than 50 years old at the time of liposarcoma diagnosis had a higher O/E ratio for second primary malignancy compared to older patients. A total of 269 patients (14.6%) developed a second cancer (O/E=1.33, 99% CI=1.15-1.54).

conclusionIn some patients with WD/DD liposarcoma, there appears to be an increased risk of having a second primary cancer. Further validation and investigation is needed, as this finding may have implications (e.g. closer screening) for patients with this disease.

Indexed as

AdultAgedAged, 80 and overFemaleHumansLiposarcomaMaleMiddle AgedNeoplasms, Second PrimaryRetroperitoneal NeoplasmsTime FactorsTomography Scanners, X-Ray ComputedepidemiologyLiposarcomasecond primary neoplasmssoft tissue sarcoma

Identifiers

PMID29848707
PMCPMC7492098
OpenAlexW2806258671

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.